Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type; F' ?' C: E5 u t
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 7 {3 ?8 f7 K q0 y
+ Author Affiliations
2 a/ O& `4 b) U- o* q, @$ B# d: B# F3 y
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 3 _7 x6 S/ q# P2 V2 k! P. i: M
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: c: g7 X W4 }) T% P9 w5 M& D+ i3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan - P: D/ p5 X7 P! u, q
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 6 z' g3 U+ _, y3 ^: p' [
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, g9 S/ Z0 _! ?4 K6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan # p3 P/ e* ?4 H- g
7Kinki University School of Medicine, Osaka 589-8511, Japan
1 D4 O# a( p4 O# ?4 N" T8Izumi Municipal Hospital, Osaka 594-0071, Japan * l/ {- o: H. T
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& }& d- K6 s" I1 O7 { jCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
7 k- s9 A# w3 ~ F* F7 o h( t) AAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ! g' B8 l! g' d( g R; p2 _
$ n. z+ L9 n" n |